Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinoic Acid in 15q11-q13 Duplication Syndrome
NCT05281965Phase 1Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tretinoin in 15q11-q13 duplication syndrome (Dup15q) and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Autism Diagnostic Observation Schedule, Second Edition at 12 months. Status: unknown.
02
Drugs
tretinoin
03
Conditions
15q11-q13 duplication syndrome (Dup15q)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05281965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281965.